The present invention describes a novel treatment for movement disorders, including tardive dyskinesia and tardive dystonia, and focal dystonias not due to neuroleptics, including blepharospasm, Meige syndrome, and occupational dystonias. The treatment of the present invention utilizes agents that act as NMDA-type glutamate receptor antagonists The invention also involves the use of an ion channel blocking agent to augment the therapeutic action of the drug treatments described. A particularly preferred ion channel blocking agent is magnesium.
* 5,602,150 Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
Please note there is up to 60 days of latency in this Status indicator for certain status conditions. You can obtain up-to-date Status indicator readings by ordering PAIR for the file.
An application with the status "Published" (which means it is pending) may be recently abandoned, but not yet updated to reflect its abandoned status. However, an application filed less than one year ago is unlikely to be abandoned.
A patent with the status "Granted" may be recently expired, but not yet updated to reflect its expired status. However, it is highly unlikely a patent less than 3.5 years old would be expired.
An application with the status "Abandoned" is almost always current, but there is a small chance it was recently revived and the status not yet updated.
This priority date is an estimated earliest
priority date and is purely an estimation. This date should not be
taken as legal conclusion. No representations are made as to the
accuracy of the date listed. Please consult a legal professional
before relying on this date.